|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date15 Nov 2022 |
对甲苯磺酰胺注射液(PTS)局部肿瘤内注射治疗中央型肺癌严重气道阻塞患者的单臂Ⅲ期临床试验研究
[Translation] A single-arm phase Ⅲ clinical trial of p-toluenesulfonamide injection (PTS) local intratumoral injection in the treatment of patients with central lung cancer with severe airway obstruction
瘤内注射PTS治疗中央型肺癌严重气道阻塞以提高管腔开放的百分比率,从而改善气道阻塞和呼吸困难
[Translation] Intratumoral injection of PTS in the treatment of severe airway obstruction in central lung cancer to increase the percentage rate of lumen patency, thereby improving airway obstruction and dyspnea
100 Clinical Results associated with Beijing Jiandakang New Drug Development Co Ltd
0 Patents (Medical) associated with Beijing Jiandakang New Drug Development Co Ltd
100 Deals associated with Beijing Jiandakang New Drug Development Co Ltd
100 Translational Medicine associated with Beijing Jiandakang New Drug Development Co Ltd